EXACT Therapeutics Partners with Agenus in Cancer Research

EXACT Therapeutics AS (DE:56F) has released an update.

EXACT Therapeutics AS, a Norwegian precision medicine company, has announced a preclinical research collaboration with Agenus Inc. to explore immune checkpoint inhibitors and Acoustic Cluster Technology in pancreatic cancer models. This partnership builds on EXACT’s immunotherapy patent and positive results from its ACTIVATE trial, showcasing the company’s commitment to advancing cancer treatment. The collaboration highlights the potential of EXACT’s ultrasound-mediated drug delivery platform across oncology and other therapeutic areas.

For further insights into DE:56F stock, check out TipRanks’ Stock Analysis page.